{"id":"short-treatment-with-benznidazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Bone marrow suppression"}]},"_chembl":{"chemblId":"CHEMBL110","moleculeType":"Small molecule","molecularWeight":"260.25"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Benznidazole is activated by parasite nitroreductase enzymes to form reactive intermediates that bind to and damage parasite DNA and proteins, leading to parasite death. It is effective against the acute phase of Chagas disease and has been studied for chronic phase treatment to reduce parasitemia and prevent disease progression. The short treatment regimen aims to optimize efficacy while minimizing cumulative toxicity.","oneSentence":"Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and proteins of Trypanosoma cruzi, the parasite causing Chagas disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:24.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chagas disease (Trypanosoma cruzi infection), chronic phase"}]},"trialDetails":[{"nctId":"NCT03672487","phase":"PHASE3","title":"Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tulane University School of Public Health and Tropical Medicine","startDate":"2019-06-01","conditions":"Chagas Disease","enrollment":273},{"nctId":"NCT06339710","phase":"PHASE3","title":"Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients","status":"WITHDRAWN","sponsor":"Evandro Chagas Institute of Clinical Research","startDate":"2025-01-30","conditions":"Chronic Chagas Disease","enrollment":""},{"nctId":"NCT04897516","phase":"PHASE3","title":"Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease","status":"RECRUITING","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2021-07-28","conditions":"Chagas Disease","enrollment":300},{"nctId":"NCT01489228","phase":"PHASE2","title":"Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease","status":"UNKNOWN","sponsor":"Drugs for Neglected Diseases","startDate":"2011-06","conditions":"Chronic Chagas Disease, Indeterminate","enrollment":230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Benznidazole 4 weeks"],"phase":"phase_3","status":"active","brandName":"Short treatment with benznidazole","genericName":"Short treatment with benznidazole","companyName":"Laboratorio Elea Phoenix S.A.","companyId":"laboratorio-elea-phoenix-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and proteins of Trypanosoma cruzi, the parasite causing Chagas disease. Used for Chagas disease (Trypanosoma cruzi infection), chronic phase.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}